JP2009543783A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543783A5
JP2009543783A5 JP2009519541A JP2009519541A JP2009543783A5 JP 2009543783 A5 JP2009543783 A5 JP 2009543783A5 JP 2009519541 A JP2009519541 A JP 2009519541A JP 2009519541 A JP2009519541 A JP 2009519541A JP 2009543783 A5 JP2009543783 A5 JP 2009543783A5
Authority
JP
Japan
Prior art keywords
substituted
alkynyl
alkoxy
alkenyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009519541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543783A (ja
JP6125741B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/015966 external-priority patent/WO2008008476A2/en
Publication of JP2009543783A publication Critical patent/JP2009543783A/ja
Publication of JP2009543783A5 publication Critical patent/JP2009543783A5/ja
Application granted granted Critical
Publication of JP6125741B2 publication Critical patent/JP6125741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009519541A 2006-07-12 2007-07-11 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達 Active JP6125741B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83057206P 2006-07-12 2006-07-12
US60/830,572 2006-07-12
PCT/US2007/015966 WO2008008476A2 (en) 2006-07-12 2007-07-11 Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014217097A Division JP2015062421A (ja) 2006-07-12 2014-10-24 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達

Publications (3)

Publication Number Publication Date
JP2009543783A JP2009543783A (ja) 2009-12-10
JP2009543783A5 true JP2009543783A5 (enExample) 2010-07-08
JP6125741B2 JP6125741B2 (ja) 2017-05-17

Family

ID=38923923

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009519541A Active JP6125741B2 (ja) 2006-07-12 2007-07-11 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達
JP2014217097A Pending JP2015062421A (ja) 2006-07-12 2014-10-24 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014217097A Pending JP2015062421A (ja) 2006-07-12 2014-10-24 可逆的なホスホトリエステル電荷中和保護基による核酸の形質導入可能な送達

Country Status (7)

Country Link
US (1) US20090093425A1 (enExample)
EP (1) EP2046964B1 (enExample)
JP (2) JP6125741B2 (enExample)
CN (1) CN101506368B (enExample)
AU (1) AU2007272906B2 (enExample)
CA (1) CA2659103C (enExample)
WO (1) WO2008008476A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984399A4 (en) * 2006-02-10 2010-03-03 Univ California TRANSDUCIBLABLE DELIVERY OF SIRANA BY MEANS OF DSRNA BINDEDOMADE FUSIONS TO PTD / CPPS
EP2346883B1 (en) * 2008-09-23 2016-03-23 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
US10022454B2 (en) * 2008-09-23 2018-07-17 Liposciences, Llc Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
US9260493B2 (en) 2009-05-07 2016-02-16 The Regents Of The University Of California Transducible delivery of nucleic acids using modified dsRNA binding domains
US20120142763A1 (en) * 2009-06-01 2012-06-07 The Regents Of The University Of California Nucleic acid delivery compositions and methods of use thereof
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
WO2011109677A2 (en) * 2010-03-04 2011-09-09 University Of Louisville Research Foundation, Inc. Methods of increasing macropinocytosis in cancer cells
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US9303258B2 (en) * 2011-04-05 2016-04-05 The Regents Of The University Of California Method and compositions comprising small RNA agonist and antagonists to modulate inflammation
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP5435016B2 (ja) 2011-12-01 2014-03-05 株式会社デンソー 半導体装置の製造方法
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
IN2015DN01765A (enExample) 2012-08-20 2015-05-29 Univ California
CN104619844A (zh) 2012-09-12 2015-05-13 夸克制药公司 靶向p53的双链寡核苷酸分子及其使用方法
EP2895608B1 (en) 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
CN104903307A (zh) * 2012-12-06 2015-09-09 默沙东公司 二硫化物屏蔽的前体药物组合物和方法
WO2014088923A1 (en) * 2012-12-06 2014-06-12 Merck Sharp & Dohme Corp. Nucleoside kinase bypass compositions and methods
CN105189786B (zh) 2013-03-15 2018-04-03 萨特西湾医院 用作治疗癌症的疗法的靶标的falz
WO2015015498A1 (en) 2013-07-31 2015-02-05 Qbi Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
CN105452465B (zh) 2013-07-31 2019-06-21 奇比艾企业有限公司 鞘脂-聚烷基胺-寡核苷酸化合物
JP6736464B2 (ja) * 2013-08-29 2020-08-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 細胞透過性コンジュゲート及びその使用の方法
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
EP3500581A4 (en) * 2016-08-17 2021-10-06 Solstice Biologics, Ltd. POLYNUCLEOTIDE CONSTRUCTS
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE
EP3674407A4 (en) 2017-08-22 2022-01-12 National University Corporation Nagoya University MODIFIED POLYNUCLEOTIDE
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
EP0537299A1 (en) * 1990-03-29 1993-04-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6017700A (en) * 1995-08-04 2000-01-25 Bayer Corporation Cationic oligonucleotides, and related methods of synthesis and use
WO1998006437A2 (en) * 1996-08-13 1998-02-19 Chiron Corporation Compositions and methods for polynucleotide delivery
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6531590B1 (en) * 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6903077B1 (en) * 1999-01-04 2005-06-07 University Of Vermont And State Agricultural College Methods and products for delivering nucleic acids
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
EP1305333A4 (en) * 2000-07-31 2006-04-12 Active Motif PEPTIDE-MEDIATED DELIVERY OF MOLECULES IN CELLS
US7034109B2 (en) * 2000-10-13 2006-04-25 Christophe Bonny Intracellular delivery of biological effectors
CA2506714A1 (en) * 2002-11-26 2004-06-10 University Of Massachusetts Delivery of sirnas
US20060178297A1 (en) * 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US7166692B2 (en) * 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
US20060182736A1 (en) * 2003-06-10 2006-08-17 Kim Jin-Soo Transducible dna-binding proteins
WO2005084158A2 (en) * 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
US20050042603A1 (en) * 2003-07-01 2005-02-24 Allele Biotechnology & Pharmaceuticals, Inc. Compositions and methods for peptide-assisted transfection
CA2543257C (en) * 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US7514530B2 (en) * 2004-04-26 2009-04-07 Centre National De La Recherche Scientifique Peptide carrier for delivering siRNA into mammalian cells
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
MXPA06012605A (es) * 2004-05-04 2006-12-15 Nastech Pharm Co Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas.
US20060030003A1 (en) * 2004-05-12 2006-02-09 Simon Michael R Composition and method for introduction of RNA interference sequences into targeted cells and tissues
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US7084248B2 (en) * 2004-07-14 2006-08-01 Gene Tools, Llc Peptide composition and method for delivering substances into the cytosol of cells
CA2574200A1 (en) * 2004-07-21 2006-01-26 Xiao Huang Hybrid wicking materials for use in high performance heat pipes
CA2576925C (en) * 2004-08-16 2013-12-10 The Cbr Institute For Biomedical Research, Inc. Method of delivering rna interference and uses thereof
WO2006036410A2 (en) * 2004-08-27 2006-04-06 The Regents Of The University Of California Protection from and treatment of prion protein infection
US20090098049A1 (en) * 2004-09-07 2009-04-16 The Regents Of The University Of California Targeting transducible molecules to specific cell types
EP1984399A4 (en) * 2006-02-10 2010-03-03 Univ California TRANSDUCIBLABLE DELIVERY OF SIRANA BY MEANS OF DSRNA BINDEDOMADE FUSIONS TO PTD / CPPS
CN101421301A (zh) * 2006-02-10 2009-04-29 加利福尼亚大学董事会 通过dsRNA结合域与PTD/CPPS的融合物转导运输siRNA
US20120142763A1 (en) * 2009-06-01 2012-06-07 The Regents Of The University Of California Nucleic acid delivery compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2009543783A5 (enExample)
JP6884250B2 (ja) ペプチドオリゴヌクレオチドコンジュゲート
US20200392498A1 (en) Polynucleotide constructs having bioreversible and non-bioreversible groups
JP7008056B2 (ja) 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
AU2013306006B2 (en) Polynucleotides having bioreversible groups
US20160257961A1 (en) Polynucleotide constructs having disulfide groups
JP6496549B2 (ja) 脊髄性筋萎縮症における誘発されたエクソン包含
EP4058032A1 (en) Compositions for delivery of antisense compounds
AU2007272906A1 (en) Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
US20190194655A1 (en) Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
JP2019516686A5 (enExample)
Gogoi et al. Synthesis and RNA binding selectivity of oligonucleotides modified with five-atom thioacetamido nucleic acid backbone structures
TW202325846A (zh) 用於治療周邊髓鞘蛋白22相關疾病的嗎啉代寡聚物
Sood Base modified peptidic nucleic acids: synthesis and crystallographic analysis of intermediates
Prater Antisense oligonucleotides directed to the HIV-1 Rev Response Element: Effects of nucleotide modification on oligo binding affinity, nuclease stability, and cellular uptake
HK1131188A (en) Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups